Encora Therapeutics sells Encora X1, a prescription wrist-worn neurostimulation device for essential-tremor hand tremor relief.

Encora Therapeutics: Non-invasive remedy provider prioritizing work-life balance and employee benefits.
Encora Therapeutics, founded by MIT engineers, is dedicated to developing non-invasive remedies for individuals with neurological movement disorders. The company's core mission is to leverage advances in wearable technology, signal processing, and patient sensing to provide affordable and personalized solutions. Their primary product is an investigational device designed to help relieve hand tremors, aiming to enhance the independence and quality of life for patients suffering from upper limb tremors.
Notable figures affiliated with Encora Therapeutics include its founding team of MIT engineers who bring significant expertise in wearable technology and biomedical engineering. The company has garnered attention for its innovative approach to treating movement disorders without invasive procedures. Encora's key achievements include the development and ongoing research of their non-invasive device, which has the potential to significantly impact the lives of those with neurological conditions. The startup's focus on work-life balance and employee benefits also highlights its commitment to fostering a positive organizational culture.
Companies similar to Encora Therapeutics include Cala Health, electroCore, Theranica and Apex Neuro.
Encora Therapeutics was founded in 2018.
Encora Therapeutics' headquarters is located in Boston, MA, US.
As of Oct 21, 2020, Encora Therapeutics has disclosed funding of $1.7M (USD). Undisclosed round amounts are excluded.
Encora Therapeutics has 7 employees as of Feb 4, 2024.
Apex Neuro